December 9, 2009
The incidence of new hepatitis C virus infections has declined in the United States, and improvements in antiviral therapy have been dramatic. Yet a significant barrier to treatment uptake is lack of diagnosis, according to a new study by Dr. Michael L. Volk, of the University of Michigan's Division of Gastroenterology and Hepatology, and colleagues. Previous studies have predicted a two- to four-fold increase in mortality over the next 20 years due to longstanding HCV infection.
The researchers obtained treatment data through an electronic audit of US pharmacies that filled patients' new prescriptions for pegylated interferon alpha-2a and -2b (Pegasys and Peg Intron, respectively) during 2002-2007.
In 2002, there were 126,000 new prescriptions for pegylated interferon products. That declined to 83,000 prescriptions by 2007. At that treatment rate, the researchers estimated that a cumulative total of less than 1.4 million people would be treated for HCV by 2030.
Barriers to HCV screening and treatment may include lack of health insurance, limited access to care, and a lower priority for HCV screening among physicians, the study authors suggested.
"It is concerning that half of all people with hepatitis C in the US are unaware of their diagnosis," said Volk. "Even with the development of new and better medications on the horizon, such medications will have less than optimal impact unless more patients are diagnosed and referred for treatment."
The full report, "Public Health Impact of Antiviral Therapy for Hepatitis C in the United States," was published in Hepatology (2009;50(6):1750-1755).
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|What Would an HIV Cure Mean for You?|
|Condomless Anal Sex Rising in U.S. MSM With or Without HIV Infection|
|If We Act to Remove Structural, Behavioral and Social Barriers, We Can End the HIV Epidemic With the Medicines We Already Have|
|This Week in HIV Research: Immune System Differences Could Produce bNAbs; New HIV Infections Are No Longer Falling; and Zoledronic Acid May Prevent Bone Loss|
|What's the Next Game-Changer in HIV Treatment?|